MEDP - Medpace Holdings, Inc.
American Capital Management Inc. lessened its holdings in shares of Medpace Holdings, Inc. (NASDAQ: MEDP) by 2.9% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 217,947 shares of the company's stock after selling 6,427 shares during the period. Medpace accounts
Medpace (MEDP) could produce exceptional returns because of its solid growth attributes.
Dimensional Fund Advisors LP cut its position in Medpace Holdings, Inc. (NASDAQ: MEDP) by 3.0% during the undefined quarter, according to the company in its most recent disclosure with the SEC. The firm owned 348,485 shares of the company's stock after selling 10,865 shares during the period. Dimensional Fund Advisors LP owned about
Medpace Holdings demonstrates strong Q2 2026 net new business awards, with a 1.13x net book-to-bill and $3.0B backlog. Oncology bookings are robust, while cardiometabolic awards have declined; management expects mix normalization over the next year. Guidance is lifted on improved RFP trends, biotech funding breadth, and moderated cancellations, supporting growth momentum into 2027.
Arrowstreet Capital Limited Partnership grew its holdings in shares of Medpace Holdings, Inc. (NASDAQ: MEDP) by 5.5% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 395,769 shares of the company's stock after buying an additional 20,736 shares during the quarter. Arrowstreet
Medpace (MEDP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Medpace Holdings Inc. (NASDAQ:MEDP) stock is trading higher on Thursday on better-than-expected second-quarter financial results and raised its fiscal 2026 guidance.
Medpace Holdings remains a "Buy" as Q2 2026 showed broad metric improvement and an inflection point in growth trajectory. The company's net book-to-Bill ratio rebounded to 1.13x, and backlog conversion rate rose to 24.1%, signaling strong future revenue visibility. Revenue grew 17.2% YoY to $707.3M, with EPS of $4.25 beating expectations; full-year 2026 guidance was raised to $2.805B–$2.885B.
Medpace Holdings, Inc. (MEDP) Q2 2026 Earnings Call Transcript
Medpace NASDAQ: MEDP reported double-digit growth in second-quarter revenue and earnings, while management described the business environment as strong and said lower cancellations helped drive record net bookings.
Medpace (MEDP) came out with quarterly earnings of $4.25 per share, beating the Zacks Consensus Estimate of $4.08 per share. This compares to earnings of $3.1 per share a year ago.
Medpace stock surged by double digits late Wednesday helped by a big bookings beat.
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the second quarter ended June 30, 2026. Second Quarter 2026 Financial Results Revenue for the three months ended June 30, 2026 increased 17.2% to $707.3 million, compared to $603.3 million for the comparable prior-year period. On a constant currency basis, revenue for the second quarter of 2026 increased 17.2% compared to the second quarter of 2025. Backlog as of June 30, 2026 in.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Investors interested in Medical Services stocks are likely familiar with Concentra Group (CON) and Medpace (MEDP). But which of these two stocks presents investors with the better value opportunity right now?
Medpace (MEDP) closed at $530.19 in the latest trading session, marking a -1.49% move from the prior day.
On July 07, 2026, Medpace Holdings Inc (MEDP) shares fell 3.4% today to a current price of $546.29. The stock has experienced significant volatility, trading wi
MEDP's 2026 outlook highlights shifting CRO demand, longer award-to-revenue timing and steady margins, while AI investment delays near-term productivity gains.
MEDP's outlook hinges on whether strong backlog quality and metabolic demand can offset rising cancellations and softer proposal activity.
In the closing of the recent trading day, Medpace (MEDP) stood at $543.57, denoting a +2.64% move from the preceding trading day.